Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.46 |
| ▸ | BDKRB1 | P46663 | 10/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977267 | 1.00 | POLB (0.53) | POLBKCNQ1HCRTR1HCRTR2ITGB1 | |
| SCHEMBL5172768 | 1.00 | POLB (0.53) | POLBKCNQ1HCRTR1HCRTR2ITGB1 | |
| SCHEMBL13206952 | 0.91 | POLB (0.49) | POLBKCNQ1HCRTR1HCRTR2ITGB1 | |
| SCHEMBL630187 | 0.91 | ITGB1 (0.56) | POLBKCNQ1HCRTR1HCRTR2ITGB1 | |
| SCHEMBL630186 | 0.91 | ITGB1 (0.56) | POLBKCNQ1HCRTR1HCRTR2ITGB1 | |
| SCHEMBL630184 | 0.87 | KCNQ1 (0.58) | POLBKCNQ1HCRTR1HCRTR2ITGB1 | |
| SCHEMBL630183 | 0.87 | KCNQ1 (0.58) | POLBKCNQ1HCRTR1HCRTR2ITGB1 | |
| SCHEMBL629837 | 0.86 | KCNQ1 (0.62) | POLBKCNQ1HCRTR1HCRTR2ITGB1 | |
| SCHEMBL629838 | 0.86 | KCNQ1 (0.62) | POLBKCNQ1HCRTR1HCRTR2ITGB1 | |
| SCHEMBL5173103 | 0.86 | KCNQ1 (0.62) | POLBKCNQ1HCRTR1HCRTR2ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1778637-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | Aventis Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006012256-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | FKBP1A, FKBP1B, FKBP3 | POLB 4105/4885KCNQ1 4358/4885HCRTR1 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.